Abstract
Peptide immunocortin sequence corresponds to the amino acid residues 11–20 of the variable part of human immunoglobulin G1 (IgG1) heavy chain. Since immunocortin was shown previously to inhibit phagocytosis in peritoneal macrophages and ConA-induced T-lymphocytes proliferation in culture, we suggested that immunocortin administering may be of use for patients with self-immune syndrome. Immunocortin in concentration 10 μM inhibited proliferation of both antigen (myelin)-induced and ConA-induced LN lymphocytes isolated from the lymph nodes of Dark Agouti (DA) rats immunized with chorda shear. The biological trials of the synthetic immunocortin were carried out on the DA rats with induced experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. These in vivo experiments have shown that intraperitoneal injections of immunocortin in a daily dosage 100 μg per animal reduced symptoms of EAE in DA rats.
Highlights
Multiple sclerosis (MS) is debilitating autoimmune disease, which affects more than 2 million people worldwide
Some data on immunosuppressive activity of the immunocortin in vitro were published before (Mitin et al, 1993), and coincide with the idea of targeting the pathogenic lymphocytes generated in course of EAE development in vivo with the peptide
Spinal cord section taken from Dark Agouti (DA) rats immunized with Spinal cord homogenate (SCH) but not treated with immunocortin has multiple signs of inflammation seen as numerous infiltrates (Figure 2B)
Summary
Multiple sclerosis (MS) is debilitating autoimmune disease, which affects more than 2 million people worldwide. The disease begins as a relapsing disorder (relapsing remitting form of MS, RR-MS), which later become a secondary progressive (secondary progressive MS, SP-MS). Most of the current approaches for therapy of MS are based on non-specific inhibiting of immunity with immunosuppressive drugs, such as natalizumab, fingolimod, mitoxantrone, and dimethyl fumarate (Mirsky et al, 2016). A number of novel therapeutics were developed for MS treatment e.g., ocrelizumab and daclizumab, which affect immune system activity. Ocrelizumab, that is formed of humanized monoclonal antibodies (mAb) developed against CD20 marker expressed on outer membrane of the mature B cells, can inhibit proliferation of primed B lymphocytes
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
